



Stockholm, 2019-09-18

PRESS RELEASE

Patent granted in Canada

QuiaPEG Pharmaceuticals Holding AB (publ) has received a so-called "Notice of Allowance" on the granting of patents in Canada

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, announces that the company has received a so-called "Notice of Allowance" from the Canadian Patent Office.

The patent, which broadens and complements QuiaPEG's patent portfolio, and which mainly relates to the permanent pegylation technology, will provide patent protection at least until the end of 2031. QuiaPEG has already been granted patents in, amongst others, the US and EU for the technology platform with phosphotriesters as a base. It is the same phosphotriester that underlies the patent applications within the uni-Qleaver® release technology platform. The company thus has good hopes that in the future it will be able to continue to build a stable and growing patent portfolio within seven different patent families. The portfolio currently consists of 11 patents granted in both the US, EU and Canada as well as a large number of patent applications, which can provide patent protection at least up to and including 2038.

For further information contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53

E-mail: marcus.bosson@quiapeg.com

www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted, through the above contact person, for publication on September 18, 2019.